DANONE (BSN.DE) Fundamental Analysis & Valuation

FRA:BSN • FR0000120644

Current stock price

68.1 EUR
+0.6 (+0.89%)
Last:

This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BSN.DE Profitability Analysis

1.1 Basic Checks

  • BSN had positive earnings in the past year.
  • BSN had a positive operating cash flow in the past year.
  • BSN had positive earnings in each of the past 5 years.
  • In the past 5 years BSN always reported a positive cash flow from operatings.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • BSN has a Return On Assets of 4.03%. This is comparable to the rest of the industry: BSN outperforms 56.45% of its industry peers.
  • BSN's Return On Equity of 10.73% is in line compared to the rest of the industry. BSN outperforms 59.68% of its industry peers.
  • BSN has a Return On Invested Capital of 7.75%. This is in the better half of the industry: BSN outperforms 66.13% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.10%.
  • The last Return On Invested Capital (7.75%) for BSN is above the 3 year average (7.51%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROIC 7.75%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.66%, BSN is in the better half of the industry, outperforming 62.90% of the companies in the same industry.
  • BSN's Profit Margin has declined in the last couple of years.
  • BSN has a Operating Margin of 13.43%. This is amongst the best in the industry. BSN outperforms 83.87% of its industry peers.
  • BSN's Operating Margin has been stable in the last couple of years.
  • BSN has a better Gross Margin (50.62%) than 80.65% of its industry peers.
  • BSN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BSN.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
  • Compared to 1 year ago, BSN has less shares outstanding
  • The number of shares outstanding for BSN has been reduced compared to 5 years ago.
  • BSN has a worse debt/assets ratio than last year.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 2.37 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.37, BSN is in the better half of the industry, outperforming 62.90% of the companies in the same industry.
  • BSN has a debt to FCF ratio of 5.29. This is a neutral value as BSN would need 5.29 years to pay back of all of its debts.
  • BSN has a better Debt to FCF ratio (5.29) than 67.74% of its industry peers.
  • A Debt/Equity ratio of 0.73 indicates that BSN is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.73, BSN is not doing good in the industry: 61.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Altman-Z 2.37
ROIC/WACC1.22
WACC6.35%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 0.90 indicates that BSN may have some problems paying its short term obligations.
  • The Current ratio of BSN (0.90) is worse than 77.42% of its industry peers.
  • A Quick Ratio of 0.75 indicates that BSN may have some problems paying its short term obligations.
  • The Quick ratio of BSN (0.75) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.75
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BSN.DE Growth Analysis

3.1 Past

  • BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
  • The Earnings Per Share has been growing slightly by 2.61% on average over the past years.
  • The Revenue has decreased by -0.34% in the past year.
  • BSN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.93% yearly.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%

3.2 Future

  • BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.81% yearly.
  • Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 4.25% on average per year.
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue Next Year2.65%
Revenue Next 2Y3.35%
Revenue Next 3Y3.59%
Revenue Next 5Y4.25%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. BSN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 17.92 indicates a rather expensive valuation of BSN.
  • BSN's Price/Earnings ratio is in line with the industry average.
  • When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (27.95), we can say BSN is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 16.82 indicates a correct valuation of BSN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BSN is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 38.68. BSN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 17.92
Fwd PE 16.82
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BSN's Enterprise Value to EBITDA is on the same level as the industry average.
  • 67.74% of the companies in the same industry are more expensive than BSN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.03
EV/EBITDA 9.37
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.73
PEG (5Y)6.86
EPS Next 2Y6.99%
EPS Next 3Y7.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. BSN.DE Dividend Analysis

5.1 Amount

  • BSN has a Yearly Dividend Yield of 3.33%.
  • BSN's Dividend Yield is a higher than the industry average which is at 2.37.
  • Compared to an average S&P500 Dividend Yield of 1.81, BSN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.33%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years4
Div Non Decr Years5
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • 75.94% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
  • BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP75.94%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BSN.DE Fundamentals: All Metrics, Ratios and Statistics

DANONE

FRA:BSN (4/17/2026, 7:00:00 PM)

68.1

+0.6 (+0.89%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20
Earnings (Next)04-22
Inst Owners55.19%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap46.40B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.76
Price Target81.39 (19.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.33%
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years4
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.76%
PT rev (3m)0.37%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-3.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE 17.92
Fwd PE 16.82
P/S 1.7
P/FCF 17.03
P/OCF 12.28
P/B 2.74
P/tB N/A
EV/EBITDA 9.37
EPS(TTM)3.8
EY5.58%
EPS(NY)4.05
Fwd EY5.95%
FCF(TTM)4
FCFY5.87%
OCF(TTM)5.55
OCFY8.15%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.73
PEG (5Y)6.86
Graham Number46.0744 (-32.34%)
Profitability
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROCE 12.04%
ROIC 7.75%
ROICexc 9.68%
ROICexgc 76.66%
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
FCFM 9.99%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Debt/EBITDA 2.46
Cap/Depr 77.86%
Cap/Sales 3.87%
Interest Coverage 21.06
Cash Conversion 75.3%
Profit Quality 150.06%
Current Ratio 0.9
Quick Ratio 0.75
Altman-Z 2.37
F-Score7
WACC6.35%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.65%
Revenue Next 2Y3.35%
Revenue Next 3Y3.59%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.46%
EBIT Next 3Y14.84%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%

DANONE / BSN.DE Fundamental Analysis FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for DANONE?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the financial health of DANONE (BSN.DE) stock?

The financial health rating of DANONE (BSN.DE) is 4 / 10.


Can you provide the dividend sustainability for BSN stock?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.